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ABSTRACT
The consumption of a diet low in fat and enhanced by fruits and vegetables, especially rich in phenolic compounds, may reduce risks 
of many civilization diseases. The use of traditional medicines, mainly derived from plant sources, has become an attractive segment 
in the management of many lifestyle diseases. Concerning the application of dietary supplements (based on phenolic compounds) 
in common practice, the ongoing debate over possible adverse effects of certain nutrients and dosage levels is of great importance. 
Since dietary supplements are not classified as drugs, their potential toxicities and interactions have not been thoroughly evaluated. 
First, this review will introduce phenolic compounds as natural substances beneficial for human health. Second, the potential dual 
mode of action of flavonoids will be outlined. Third, potential deleterious impacts of phenolic compounds utilization will be discussed: 
pro-oxidant and estrogenic activities, cancerogenic potential, cytotoxic effects, apoptosis induction and flavonoid-drug interaction. 
Finally, future trends within the research field will be indicated. 
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daily with an estimated total consumption of 1  g/d 
(Formica & Regelson, 1995), which could be much higher 
if dietary supplements are also consumed. 
Chemically, phenolic compounds have one or more 
hydroxyl groups attached to a benzene ring. Edible 
plants contribute to the human diet more than 8  000 
different phenolic compounds that can be categorized 
as flavonoids and non-flavonoid compounds. Flavonoids 
have a common C6–C3–C6 structure consisting of two 
aromatic rings (A and B) linked through a three-carbon 
chain, usually organized as an oxygenated heterocycle 
(ring C) (Figure 1). Flavonoids can be divided into sev-
eral subfamilies according to the degree of oxidation 
of the oxygenated heterocycle as flavanols, flavanones, 
flavones, flavonols (essentially, flavan-3-ols), isoflavones, 
and anthocyanidins, the most relevant for human diets 
(Scalbert & Williamson, 2000). Starting from a basic 
chemical structure, plant biosynthetic pathways intro-
duce different hydroxyl group patterns, methyl groups, 
and sugars (Jaganatah & Crozier, 2010). In certain cases, 
oligomerization and polymerization of the flavonoid units 
occur. Oligomers and polymers of flavonoids are called 
tannins and are classified into two groups, condensed 
tannins and hydrolyzable tannins. Condensed tannins 
(also known as proanthocyanidins or procyanidins) are 
oligomers of flavanols, and their chemical structures 
Introduction
Phenolic compounds are constituents of fruits, veg-
etables, nuts, plant-derived beverages – tea and wine, 
and traditional Eastern medicines such as Ginkgo biloba, 
as well as components present in a plethora of herbal 
dietary supplements. Humans have consumed flavonoids 
and other dietary phenolics since the arrival of human 
life on earth. Over 4  000 different naturally occurring 
phenolic compounds have been described (Middleton & 
Kandaswami, 1986) and the list is still growing.
Plants produce phenolic compounds as secondary 
metabolites involved in diverse processes, such as growth, 
lignification, pigmentation, pollination, and resistance 
against pathogens, predators, and environmental stresses 
(Duthie et al., 2003; Fraga et al., 2010). 
Phenolic compounds have been known as plant pig-
ments for over a century and belong to a vast group widely 
distributed in all foods of plant origin. In the normal 
North American diet they are unavoidably consumed 
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are defined not only by the kind of monomer, but also 
according to the kind of link among monomers. There are 
several oligomerization patterns and some plants present 
characteristic manners of oligomerization, e.g. in cocoa 
the monomeric units are linked through 4→8 carbon–
carbon bonds forming mostly B-type dimers (Jaganatah & 
Crozier, 2010). Hydrolyzable tannins are polymers readily 
hydrolyzed by acids into their components: a central core 
constituted by a polyol (a sugar, generally D-glucose, or 
a flavonoid, as catechin) and a phenolic carboxylic acid 
esterifying partially or totally the core molecule. These 
tannins are classified according to the phenolic carboxylic 
acids present, which could be gallic acid (gallotannins) or 
ellagic acid (ellagitannins) (Jaganathan & Mandal, 2009).
Overall compelling data from in vitro and in vivo 
laboratory studies, epidemiological investigations, and 
human clinical trials indicate that phenolic compounds 
are beneficial for human health. A large number of studies 
have identified cellular targets that could be involved in 
the health promoting actions of dietary plant phenolic 
compounds. Epidemiological evidence indicates that 
diets rich in fruits and vegetables promote health and 
attenuate or delay the onset of many diseases (Knekt et 
al., 2002; Ghosh & Konishi, 2007; Rhone & Basu, 2008; 
Patil et al., 2009; Agte & Tarwadi, 2010; Cvorovic et al., 
2010; Crozier et al., 2010; Ziberna et al., 2010; Kalt et al., 
2010). The beneficial effects of fruits and vegetables have 
been largely ascribed to phenolic compounds, since inges-
tion of foods rich in these substances has been associated 
in humans and experimental animals with reduction 
in: i) dyslipidemia and atherosclerosis; ii) endothelial 
dysfunction and hypertension; iii) platelet activation and 
thrombosis; iv) inflammatory processes associated with 
induction and perpetuation of cardiovascular diseases 
(Fraga et al., 2010). 
Guarrera et al. (2007) found a flavonoid-rich diet to be 
likely to have beneficial health effects through modulat-
ing the expression of certain genes that have been clearly 
related to disease risk. Likewise, Halliwell (2007) summa-
rized in his review the potential of phenolic compounds 
to protect against cardiovascular disease, supporting this 
conception by much convincing evidence from a number 
of pre-experimental models.
Anthocyanidins have been suggested as useful agents 
in disease prevention (Wang & Stoner, 2008; Cvorovic et 
al., 2010). Recent studies showed their ability to trigger 
apoptosis in human leukemia cell lines through induction 
of oxidative stress (Hou et al., 2003; Feng et al., 2007) and 
their potential role in cancer therapy (Syed et al., 2008).
With the increasing interest in alternative medicine, 
herbal products are ingested by at least 10% of the gen-
eral population and 30–70% of individuals with specific 
disease states (Ni et al., 2002; Galati & O´Brien, 2004). 
However, dietary supplements are not classified as drugs 
and do not require Food and Drug Administration (FDA) 
approval to be marketed. The potential toxicities and drug 
interactions have not been evaluated thoroughly, yet they 
should be considered. Thus, the main goal of this review 
will be to focus on different possible deleterious impacts 
of flavonoid utilization: pro-oxidant and estrogenic activi-
ties, cancerogenic potential, cytotoxic effects, apoptosis 

















Figure 1. Various types of common fl  avonoids, basic structures of fl  avone, fl  avonol, fl  avanone, fl  avan-3-ol, anthocyanidin 
and isofl  avone. At the structure of fl  avone marks for benzene rings: A, B, and C are indicated. 175
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Potential dual mode of action 
of phenolic compounds
Phenolic compounds might exert modulatory effects in 
cells independent of classical antioxidant capacity through 
selective actions at different components of a number of 
protein kinase and lipid kinase signaling cascades such as 
phosphoinositide 3-kinase (PI 3-kinase), Akt/PKB, tyrosine 
kinases, protein kinase C (PKC), and mitogen-activated 
protein kinases (MAPKs) (Kong et al., 2000; Schroeter et 
al., 2001; Spencer et al., 2003a). Inhibitory or stimulatory 
actions at these pathways are likely to profoundly affect 
cellular function by altering the phosphorylation state of 
target molecules and/or by modulating gene expression. 
Although selective inhibitory actions at these kinase cas-
cades may be beneficial in cancer, proliferative diseases, 
inflammation, and neurodegeneration, they could be det-
rimental during development, particularly in the immature 
nervous system, when protein and lipid kinase signaling 
regulates survival, synaptogenesis, and neurite outgrowth 
(Williams et al., 2004). Thus flavonoid interactions with 
intracellular signaling pathways could have unpredictable 
outcomes, depending on the cell type, the disease studied, 
and the stimulus applied.
Antioxidant activity of phenolic compounds can be 
described directly, in terms of their per se activity as free 
radical scavengers, or indirectly as modulators of intracel-
lular pro- and anti-oxidant enzymes (Schewe et al., 2008). 
However, in recent years, both antioxidant and pro-oxidant 
activities were reported, depending upon certain experi-
mental conditions (Halliwell, 2008; Ziberna et al., 2010). 
Often these pro-oxidant effects involve interactions of 
phenolic compounds with transition metal ions, which 
can be ubiquitously found in biologic systems, or as uni-
versal contaminants of biologic reagents (Halliwell, 2009).
Kong  et al. ( 2 0 0 0 )  p r o v i d e d  e x a m p l e s  o f  m a n y  
natural products eliciting diverse pharmacological effects. 
Studying two classes of potential chemopreventive com-
pounds, phenolic compounds and isothiocyanates, they 
reviewed the potential utility of two signaling events, 
MAPKs and ICE/Ced-3 proteases (caspases) stimulated 
by these agents in mammalian cell lines. Studies with 
phenolic antioxidants (butylated hydroxyanisole – BHA, 
tert-buthyl hydrochinone – tBHQ) and natural products 
(either flavonoids epigallocatechin-3-gallate – EGCG and 
epicatechin 3-gallate – ECG or isothiocyanates phenethyl 
isothiocyanate  – PEITC and sulforaphane) provided 
important insights into the signaling pathways induced by 
these compounds. At low concentrations, these chemicals 
activated the MAPKs (ERK2, JNK1, p38) leading to expres-
sion of genes provoking protective mechanisms (homeo-
stasis response). However, to the contrary, on increasing 
their concentrations, these compounds additionally acti-
vated the caspase pathway, leading to apoptosis (potential 
cytotoxicity). Further increments to supra-pharmacolog-
ical concentrations would inevitably lead to nonspecific 
necrotic cell death. This study revelaed the respective in 
vivo therapeutic window for the compounds tested and 
also extended knowledge about their efficacy and safety.
Another very good example is the flavonol quercetin – 
one of the most frequently researched flavonoids, with well 
described beneficial (Oyama et al., 1999) and/or deleterious 
effects (Metodiewa et al., 1999; Rzymowska et al., 1999; 
Rong et al., 2000; Spencer et al., 2003b) on different cell 
types. Its exact mechanism of action remains however still 
unclear. Quercetin has been thoroughly investigated for 
its abilities to express antiproliferative effects (Kuo, 1996; 
Csokay et al., 1997) and induce cell death predominantly by 
an apoptotic mechanism in cancer cell lines (Wei et al., 1994; 
Wang et al., 1999; Russo et al., 1999; Williams et al., 2004).
Based on the structural properties of quercetin, 
Metodiewa et al. (1999) investigated whether its catechol 
moiety may be the potential tool for the revealed toxicity. 
Their results were indicative of intracellular metabolic 
activation of quercetin to o-quinone, a process which can 
be partially associated with its observed concentration-
dependent cytotoxic effect. 
Similarly, Spencer et al. (2003a) observed a dual quer-
cetin effect on intracellular signaling pathways such as the 
MAPKs cascade. They investigated whether the observed 
strong neurotoxic potential of quercetin in primary cortical 
neurons may occur via specific and sensitive interactions 
within neuronal mitogen-activated protein kinase and Akt/
protein kinase B (PKB) signaling cascades, both implicated 
in neuronal apoptosis. High quercetin concentrations 
(30  μM) led to sustained loss of Akt phosphorylation 
and subsequent Akt cleavage by caspase-3, whereas at 
lower concentrations (<10  μM) the inhibition of Akt 
phosphorylation was transient and eventually returned 
to basal levels. Lower levels of quercetin also induced 
strong activation of the pro-survival transcription factor 
cyclic adenosine monophosphate (cAMP)-responsive 
element-binding protein, although this did not prevent 
neuronal damage. The glucuronide of quercetin was not 
toxic and did not evoke any alterations in neuronal sig-
naling, probably reflecting its inability to enter neurons. 
Recently, Angelone et al. (2010) analyzed whether two 
red wine phenolic compounds, quercetin and myricetin, 
affect mammalian basal myocardial and coronary func-
tion. Quercetin induced dual inotropic and lusitropic 
effects, positive at lower concentrations and negative 
at higher concentrations. Contrarily, myricetin elicited 
coronary dilation, without affecting contractility and 
relaxation. Simultaneous administration of the two phe-
nolic compounds induced only vasodilation. Quercetin-
elicited positive inotropism and lusitropism depend on 
beta1/beta2-adrenergic receptors and are associated with 
increased intracellular cAMP, while the negative inotro-
pism and lusitropism observed at higher concentrations 
were alpha-adrenergic-dependent. 
Possible deleterious impacts of 
utilizing phenolic compounds 
Pro-oxidant activities
The chemopreventive properties of phenolic compounds 
are generally believed to reflect their ability to scavenge 176
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endogenous reactive oxygen species (ROS). However, the 
pro-oxidant action of plant-derived phenolics rather than 
their antioxidant action may be an important mechanism 
for their anticancer and apoptosis-inducing properties, as 
ROS can mediate apoptotic deoxiribonucleic acid (DNA) 
fragmentation (Rahman et al., 1990; Haidi et al., 2000; 
Ahmad et al., 2000; Galati & O´Brien, 2004). 
Certain properties of dietary phenolic compounds, 
such as binding and cleavage of DNA and the generation 
of ROS in the presence of transition metal ions (Rahman et 
al., 1990) are similar to those of known anticancer drugs. 
A putative mechanism has been proposed for the antican-
cer and apoptosis-inducing properties of plant-derived 
dietary phenolic compounds, which is a mechanism of 
DNA fragmentation that involves the mobilization of 
intracellular and extracellular copper (Haidi et al., 2000). 
As an example, the reaction mechanism of DNA cleavage 
by resveratrol and Cu2+ was investigated by researchers of 
another laboratory, who found that resveratrol formed a 
complex with Cu2+, reducing it to Cu+, with the formation 
of one or more ‘‘oxidized species’’ of resveratrol (Ahmad 
et al., 2000). The authors then demonstrated that the 
oxidized products of resveratrol were capable of reducing 
Cu2+ to Cu+. When calf thymus DNA was treated with 
increasing molar ratios of Cu2+ and resveratrol, the con-
comitant efficiency of DNA cleavage was increased (Haidi 
et al., 2000).
Dietary phenolics have been shown to act as pro-
oxidants in systems containing redox-active metals. In 
the presence of oxygen (O2), transition metals such as 
copper and iron catalyze the redox cycling of phenolics, 
leading to the formation of ROS and phenoxyl radicals 
that can damage DNA, lipids, and other biological mol-
ecules (Decker, 1999; Yamanaka et al., 1999). Exposure 
of DNA to dihydrocaffeic acid in the presence of copper 
resulted in more DNA single- and double-strand breaks 
than exposure to caffeic acid, whereas chlorogenic acid 
caused only minimal damage, although these phenolics 
had similar structures and redox potential (Sakihama 
et al., 2002). The green tea catechin EGCG was recently 
shown to induce hydrogen peroxide (H2O2) generation 
and cause subsequent oxidative damage to isolated and 
cellular DNA in the presence of transition metal ions 
(Furukawa et al., 2003). 
Galati and O´Brien (2004) showed that upon oxida-
tion by peroxidase/H2O2  catalytic concentrations of 
flavonoids with a phenol B ring (e.g. apigenin, naringenin) 
formed phenoxyl radicals and generated ROS. Moreover, 
they found that phenol ring-containing dietary flavonoids 
and other phenolics also caused glutathione oxidation in 
isolated rat hepatocytes (Galati et al., 2002). Consumption 
of large amounts of phenolic compounds in the form of a 
concentrated supplement may not be considered safe until 
their in vivo potential for oxidative stress is evaluated.
Estrogenic activities
Overall, flavonoids are considered to be nonestrogenic 
or weakly estrogenic. However, some flavones and flavo-
nols (apigenin, kaempferol, and naringenin) act through 
estrogen-receptor mediated mechanisms and have been 
shown to have antiestrogenic effects similar to those of 
isoflavones in breast cancer cell cultures (Miksicek, 1995; 
Ross and Kasum, 2002). Apigenin and kaempferol are the 
most active flavonoids and inhibit estrone reduction at a 
concentration of 0.12 μmol/L (Makela et al., 1998). Some 
flavones were shown to inhibit the 17β-oxidation of tes-
tosterone and estradiol to the less active steroids andro-
stenedione and estrone. In addition, flavonoids inhibit 
placental aromatase (Kellis & Vickery, 1984; Ibrahim & 
Abdul-Hajj, 1990).
Isoflavones are diphenolic compounds structurally 
or functionally similar to endogenous estrogens and 
they display agonistic and antagonistic interactions with 
estrogen receptors (Wang et al., 2008). Their biological 
activity is partly ascribed to the structural similarities 
with the primary physiologically relevant estrogen – 
17β-estradiol (E2). They bind to and activate intracel-
lular estrogen receptors ERα and ERβ and, mimicking 
the effects of estrogen, are commonly referred to as 
phytoestrogens. In most systems, the relative binding 
affinities of genistein and daidzein are greater for ERβ 
than for ERα, while E2 binds to both receptors with 
approximately equal affinities (Messina et al., 2006). The 
estrogenic activities of soy isoflavones are thought to play 
an important role by their health-enhancing properties 
in menopausal symptoms and in treating osteoporosis 
(Lockwood, 2008).
Phytoestrogens are phenolic nonsteroidal plant com-
pounds with estrogen-like biological activity. Most flavo-
noids are nonestrogenic or weakly estrogenic; however, 
the isoflavones such as genistein, other flavonoids such as 
apigenin and kaempferol, and the polyphenolic stilbenes 
such as resveratrol act through estrogen receptor-medi-
ated mechanisms and also have antiestrogenic effects 
(Cos et al., 2003). The use of phytoestrogens to protect 
against hormone dependent cancers or as a ‘‘natural’’ 
alternative to hormone replacement therapy remains con-
troversial. There is a paucity of data on endocrine effects 
of soy phytochemicals such as genistein and daidzein 
during infancy, the most sensitive period of life for the 
induction of toxicity. The safety of isoflavones in infant 
formulas has been questioned recently owing to reports 
of possible hormonal effects (Miniello et al., 2003). Closer 
studies are necessary both in experimental animals and 
human populations exposed to phytoestrogen containing 
products, and particularly to soy-based infant formulas, 
as the estrogenic activity of genistein at high doses has 
been shown to be associated with decreased fertility and 
increased sexual dysfunction in experimental animals 
(You et al., 2002). There is also an increased risk for breast 
and reproductive tract cancers in humans. Estrogenic 
activity in soybean-related foodstuffs is mostly due to 
genistein, yet 8-prenylnaringenin, the active principle in 
beer, is 10 times more active than genistein (Takamura-
Enya et al., 2003).
Since overexposure to estrogen is a major contributing 
factor in the development of breast cancer, the relation-
ship between soyfoods and breast cancer has become 177
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controversial. Concern has been raised that soy-derived 
isoflavones, which exhibit estrogen-like properties 
under certain experimental conditions, may stimulate 
the growth of existing estrogen sensitive tumors. This 
concern is substantiated by evidence showing that isofla-
vones bind and transactivate estrogen receptors and elicit 
estrogenic effects in rodent reproductive tissues. Limited 
human data directly address the tumor promoting effects 
of isoflavonoids (Messina et al., 2006). Due to its estro-
genic properties genistein at low physiologically relevant 
levels may stimulate estrogen receptor positive tumors, 
while at higher levels, anticancer actions of isoflavonoids 
may predominate (Duffy et al., 2007). 
Estrogen-like effects have raised concern regarding 
soy/isoflavone consumption, particularly in postmeno-
pausal women at high risk of breast cancer. Currently, 
there is little evidence to suggest that any potential weak 
estrogenic effects of dietary isoflavones would have a 
clini cally  r e l evan t  im pa ct  o n  b r east  tissu e  in  h eal th y  
women or in breast cancer survivors (Messina and Wood, 
2008). 
However, recent epidemiologic evidence showed that 
higher soy intake in Asian women was associated with 
a nearly one-third reduction in breast cancer risk and 
that Japanese breast cancer patients, in comparison to 
Western women, exhibited better survival rates even after 
the controll stage (Miadokova, 2009).
The developing fetus is partucularly sensitive to per-
turbation with estrogenic chemicals. The carcinogenic 
effect of prenatal exposure to diethylstilbestrol (DES) is 
a classic example: exposure to exogenous estrogens can 
induce both structural and functional changes in the 
developing reproductive tract of males. Men exposed to 
diethylstilbestrol (DES) in utero, for example, experienced 
DES-induced lesions ranging from relatively minor struc-
tural alterations to more severe changes such as testicular 
hypoplasia (Gill, 1988). It is possible that other exogenous 
estrogens, including flavonoids, may alter reproductive 
tract development in males. 
Since phytoestrogen use in nutritional and pharma-
ceutical applications for infants and children is increas-
ing, Newbold et al. (2001) investigated the carcinogenic 
potential of genistein, a naturally occurring plant estro-
gen in soy. In an experimental animal model they found a 
high incidence of uterine adenocarcinoma after neonatal 
DES exposure. Outbred female CD-1 mice were treated 
on postnatal days 1–5 with equivalent estrogenic doses 
of DES (0.001  mg/kg/day) or genistein (50  mg/kg/day). 
At 18 months, the incidence of uterine adenocarcinoma 
was 35% for genistein and 31% for DES. These data clearly 
indicate that genistein is carcinogenic if exposure occurs 
during critical periods of differentiation. 
Thus, the use of soy-based infant formulas in the 
absence of medical necessity and the marketing of soy 
products designed to appeal to children should be closely 
examined. Given the increasing use and marketing of 
soy formulas, soy products, and phytoestrogen contain-
ing dietary supplements, further studies of the potential 
detrimental effects are needed.
Cancerogenic potential
Flavonoids are phytochemicals that belong to popular 
chemopreventive compounds exerting a great variety 
of beneficial effects on human health, e.g. antiallergic, 
antiinflammatory, antiviral, antiproliferative, anticarci-
nogenic (Birt et al., 2001). Their biological activities arise 
mainly from their antioxidant properties and abilities to 
modulate several enzymes or cell receptors (Klejdus et 
al., 2005). Although flavonoids are often considered to be 
safe because of their “plant origin”, ingestion of flavonoids 
should be taken with caution. Some flavonoids show the 
ability of direct interaction with DNA and/or enhance car-
cinogenic activation into DNA modifying agents (Hodek 
et al., 2006). Enhanced expression of cytochrome P450 
(CYP) in colon tissue might be responsible for increasing 
incidence of colorectal carcinoma in humans (Hodek et 
al., 2006). Some flavonoids have mutagenic (e.g. quercetin) 
and/or pro-oxidant effects and they may interfere with 
essential biochemical pathways (Rietjens et al., 2005).
In spite of a long history of use, botanical or herb-
based preparations may contain individual ingredients 
known to be toxic and even genotoxic and carcinogenic. 
The mutagenic properties of the flavonoid quercetin were 
demonstrated in a variety of bacterial and mammalian 
mutagenicity tests, and were related to its quinone/
quinone methide chemistry (Brown, 1980). For quercetin 
a metabolic pathway for activation into DNA-reactive 
species may include enzymatic and/or chemical oxida-
tion of quercetin to quercetin ortho-quinone, followed by 
isomerization of the ortho-quinone to quinone methides. 
These quinine methides are suggested to be the active 
alkylating DNA-reactive intermediates. Recent results 
showed formation of quercetin DNA adducts in exposed 
cells in vitro (Walle et al., 2003).
Quercetin at higher doses was able to inhibit cell pro-
liferation (van der Woude et al., 2003). Evidence of its car-
cinogenic activity was found in male F344/N rats exposed 
to quercetin (Dunnick et al., 1992). Moreover, Pamukcu 
et al. (1980) reported bladder tumors in rats exposed to 
quercetin. However, in several other animal studies no 
tumor initiating activity was reported (Morino et al., 
1982; Hirose et al., 1983; Ito et al., 1989). The relevance 
for the human in vivo situation as well as the mechanism 
behind the possible quercetin-mediated carcinogenic 
effect remains a matter of debate.
One of the questions that remains to be answered is 
why these genotoxic characteristics of quercetin obtained 
in vitro, and even carcinogenicity data obtained in vivo in 
animal studies using high doses of pure compounds, do 
not necessarily lead to carcinogenic risks.
I t  s h o ul d  be  also  n o ted  tha t  animal  car cin og e ni c -
ity experiments are conducted with pure compounds, 
whereas human dietary exposure generally occurs in a 
complex food matrix containing other (herbal) ingredi-
ents. In a complex food matrix, interactions occur that 
can affect the bioavailability of food components (Schiller 
et al., 2003; Crozier et al., 2010; Rietjens et al., 2010). For 
example, a slow or incomplete release from the matrix 
could result in  a reduced bioavailability as compared to 178
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bioavailability when dosed as a pure compound by oral 
gavage. In addition to the effect of the food matrix on the 
bioavailability, interactions with other herbal ingredients 
might occur at the level of metabolic activation and/or 
detoxification (Rietjens et al., 2010). 
The flavonoid genistein was one of the most active 
compounds tested that stimulated enzyme-mediated 
DNA cleavage approximately tenfold without requiring 
redox cycling for activity (Ferguson & Philpott, 2008). 
Flavonoids of this type have been suggested as etiologi-
cal agents in specific types of childhood leukemia that is 
characterized by a distinctive chromosomal translocation 
(Ross et al., 1994). Although epidemiology has provided 
some evidence for this hypothesis, it is difficult to be cer-
tain of the contribution of one component in a complex 
mixture. However, the recent finding (van Waalwijk van 
Doorn-Khosrovani et al., 2007) that kaempferol, genistein, 
and quercetin induce myeloid/lymphoid or mixed-lineage 
leukemia translocations in primary human stem cells 
with characteristics of the translocations in this leukemia 
is entirely consistent with this hypothesis. Although the 
topoisomerase II inhibitory properties associated with 
quercetin might imply that it is an effective mutagen and 
potential dietary hazard, other studies point to antimu-
tagenic effects. For example, Steiner et al. (2007) showed 
that preincubation of MCF-10A cells with genistein 
reduced DNA damage caused by two potential dietary 
mutagens – 4-hydroxy-2-nonenal (150 μM) and benzo(a)
pyrene-7,8-dihydrodiol-9,10-epoxide (50  μM). The 
mechanism appeared to proceed through upregulation of 
glutathione-S-transferases, and the authors extrapolated 
these results to suggest the potential of this mechanism 
in preventing genotoxic injury in the etiology of breast 
cancer.
Induction of CYP by flavonoids might also significantly 
affect the plasma concentrations of pharmaceutical drugs, 
resulting in a loss of therapeutic effect or an overdose. CYP 
induction could also increase the metabolic activation of 
carcinogens. Certain flavonoids, like some other xenobiot-
ics including 2,3,7,8-tetrachlorodibenzo-p-dioxin, induce 
CYPs via binding to aryl hydrocarbon receptor (AhR) 
(Kohn et al., 2001). This mechanism is associated with 
an elevation in the activities of the CYP1 family enzymes 
that are responsible for the activation of carcinogens, such 
as meat-derived heterocyclic aromatic amines, benzo[a]
pyrene, aflatoxin B1, and 7,12-dimethylbenz[a]anthracene 
(Omiecinski et al., 1999). Many flavonoids are AhR ligands 
because the binding affinities for AhR seem to be largely 
dependent on structural constraints, including planar 
aromatic compounds with few bulky substituent groups 
(Waller and McKinney, 1995). Flavonoids have often been 
shown to act as AhR agonists and to induce CYP1A1 
and CYP1A2 activities. Galangin, quercetin, diosmin, 
and diosmetin are examples of flavonoids that increase 
transcription of the CYP1A1 gene, whereas others, like 
flavone, tangeretin, and synthetic h-naphthoflavone, are 
flavonoids that induce CYP1A1/2 and to some extent 
CYP2B1/2 (Hodek et al., 2002). Flavanone is a specific 
inducer of CYP2B1/2 (Canivenc-Lavier et al., 1996). 
Aromatic amine carcinogens are metabolically activated 
by CYP1A2, whereas polycyclic aromatic hydrocarbon 
carcinogens are metabolically activated by CYP1A1 
(Galati and O´Brien, 2004).
Cytotoxicity
The cellular effects of flavonoids will ultimately depend 
on the extent to which they associate with cells, either 
by interactions at the membrane or by uptake into the 
cytosol. Information regarding uptake of flavonoids and 
their metabolites from the circulation into various cell 
types and their further assumed modification by cell 
interactions has become increasingly important as atten-
tion focuses on the new concept of flavonoids as potential 
modulators of intracellular signaling cascades vital to 
cellular function (Williams et al., 2004).
Resveratrol and the citrus flavanones hesperetin and 
naringenin were reported to have inhibitory activity at a 
number of protein kinases (So et al., 1996; Huang et al., 
1999; Fischer et al., 2000). This inhibition is mediated via 
binding of the phenolic compounds to the ATP binding 
site, presumably causing three-dimensional structural 
changes in the kinase leading to its inactivity. Flavonoids 
may also interact with mitochondria, interfere with path-
ways of intermediary metabolism, and/or downregulate 
the expression of adhesion molecules (Panes et al., 1996; 
Soriani et al., 1998). 
Cvorovic et al. (2010) recently observed a dual role 
for anthocyanidins, depending on cell type. In cells 
with low basal metabolic rates such as tumor cells with 
low proliferation rate and low malignant potency (e.g. 
Caco-2 cells), they behave as free radical scavengers and 
protect them from oxidative stress. On the other hand, 
in malignant cell, with active metabolism, high intrinsic 
ROS production, and drug-resistance (such as LoVo/ADR 
cells), delphinidin and cyanidin acted as pro-oxidants, 
putatively both by reduced capacity to scavenge reactive 
oxygen species and by depletion of the glutathione pool. 
Indeed, they found that delphinidin and cyanidin were 
cytotoxic in the metastatic human colorectal cancer cell 
lines LoVo and LoVo/ADR, where they inactivated the 
glutathione antioxidant system and promoted oxidative 
stress. Anthocyanidins were studied because in the colon 
they can be released from dietary anthocyanins by the 
action of glycosidases of the colonic microflora (Talavera 
et al., 2005), though they are less stable than their gly-
cosylated precursors at neutral pH, yielding phenolic 
aldehydes and phenolic acids (Woodward et al., 2009), 
apparently mimicking in vivo conditions.
Similarly, Ziberna et al. (2010) described anthocyanins 
as exerting cardioprotective activities in low concentra-
tions and cardiotoxic activities in high concentrations. 
They were first to report that high concentrations of 
anthocyanins exerted deleterious effects in ischemic-
reperfusion injury on the isolated heart. They observed 
that bilberry anthocyanins induced a dual inotropism: 
positive at lower concentrations and negative at higher 
concentrations. This effect is in agreement with a similar 
study done with quercetin (Angelone et al., 2010).179
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Apoptosis induction
Another mechanism proposed for the anticancer and 
tumor cell apoptosis-inducing properties of flavonoids is 
that their pro-oxidant phenoxyl radicals cause mitochon-
drial toxicity by collapsing the mitochondrial membrane 
potential. Apoptosis (programed cell death) is required 
to maintain a balance between cell proliferation and cell 
loss. Misregulation of this balance can lead to malignant 
transformation, whereas induction of apoptosis sup-
presses the development of cancer (Tang & Porter, 1996; 
Bhat and Pezzuto, 2002). Various diet-derived compounds, 
e.g., resveratrol, have been shown to induce apoptosis in 
malignant cells and provide a promising natural strategy 
to prevent cancer (Katdare et al., 1999; Surh et al., 1999). 
It has been proposed that opening of the mitochondrial 
permeability transition pore (PTP) and/or mitochondrial 
membrane permeabilization (MMP) signals cell death by 
releasing apoptogenic factors, e.g., cytochrome c, from the 
mitochondria. Dissipation of the mitochondrial mem-
brane potential (Dcm) is an early event and the release of 
cytochrome c was shown to occur in a variety of models 
relatively early during cell death (Goldstein et al., 2000). 
Cells with collapsed Dcm are irreversibly committed to 
undergo death, even when the apoptosis-inducing trigger 
is withdrawn, and this marks the point of no return in the 
cell death process (Kroemer, 2003). Curcumin, a dietary 
phenolic compound, also opened the PTP and induced 
mitochondrial swelling, calcium release, respiration 
impairment and collapsed the mitochondrial membrane 
potential (Kim et al., 2003). Baicalin is a major component 
of the herbal medicine Sho-saiko-to, commonly used for 
treating chronic hepatitis in Japan and China. Baicalin 
induced apoptosis of Jurkat cells, a leukemia-derived T 
cell line, which was accompanied by intracellular ROS 
generation, mitochondrial cytochrome c release, and 
disruption of Dcm before activation of caspase 3. This 
suggests that baicalin acts as a pro-oxidant and induces 
mitochondrial-mediated apoptosis (Ueda et al., 2001). 
Nordihydroguaiaretic acid (NDGA) found in chaparral, 
herbal medicine, is also a mitochondrial toxin (Biswal et 
al., 2000). Furthermore, the isoflavone analog rotenone 
is a classical complex I inhibitor of the mitochondrial 
respiratory chain (Degli Esposti, 1998) and its analogs 
have been shown to be effective anticancer agents (Fang 
& Casida, 1998).
Epidemiological studies suggest that consumption of 
green tea is associated with a lower risk of several types of 
cancers, including stomach, esophagus, and lung (Chung 
et al., 2001). The growth suppressive effect of green tea 
flavonoids and gallic acids is at least partly due to the 
induction of apoptosis (Paschka et al., 1998). 
Epigallocatechin was also shown to have antiprolif-
erative and anticarcinogenic activities: mitochondrial 
depolarization and ROS formation were suggested to be 
early processes leading to EGCG-induced apoptosis of 
human prostate and lung carcinoma cells (Chung et al., 
2001; Yang et al., 1998). 
Flavopiridol is widely used in traditional medicine and 
is a novel semisynthetic flavone analog of rohitukine, a 
leading anticancer compound derived from an Indian 
tree. Flavopiridol caused apoptosis in human chronic 
lymphocytic leukemia cells, and the cytotoxic mechanism 
involved caspase 3 activation (Byrd et al., 1998).
Wenzel  et al. (2000) evaluated how the core struc-
ture of the flavones, 2-phenyl-4H-1-benzopyran-4-one, 
affected proliferation, differentiation, and apoptosis in a 
human colon cancer cell line. In particular, they evaluated 
the effect of the flavone on the expression of cell-cycle 
and apoptosis-related genes in the cell line. They reported 
d r a m a t i c  c h a n g e s  i n  m R N A  l e v e l s  o f  s p e c i f i c  g e n e s  
including cyclo-oxygenase-2, nuclear transcription factor 
kappaB, and bcl-X. Further, there was high selectivity for 
apoptosis in the transformed cells. The authors concluded 
that flavones could be a new chemopreventive agent. 
In addition to effects on mRNA levels of genes impor-
tant in cell cycle control and apoptosis, flavonoids have 
been investigated with respect to their interaction with 
enzymes associated with DNA topology. DNA topoisom-
erase II is an enzyme that catalyzes the double-strand 
breakage and rejoining of DNA; it is pivotal for several cell 
functions (Gerwirtz, 1991). Several flavonoids, including 
genistein, can inhibit DNA topoisomerase II activity 
by stabilizing the cleavage complex, thereby facilitating 
apopotosis (Strick et al., 2000). Importantly, however, 
specific flavonoids have been shown to cause single- and 
double-strand DNA breaks in cultured human cells 
(Strick et al., 2000), suggesting that not all cells undergo 
apoptosis in the presence of specific flavonoids. This 
observation is extremely important in understanding the 
potential detrimental effects that may be associated with 
DNA topoisomerase II inhibition (Ross, 1998; Ross and 
Kasum, 2002).
Interactions of phenolic compounds with drugs 
Plants have long been used to treat some of the most com-
mon diseases in humans, but the effects of herbal medici-
nal products have not always been adequately investigated 
by pharmacological studies. For this reason the European 
Medicines Agency (EMA) is promoting European 
Community monographs on herbal medicinal products in 
order to assess their clinical safety and efficacy (Schilter 
et al., 2003; EMEA Commitee on HMPC, 2006; Colalto, 
2010). One safety threatening aspect is the risk of adverse 
effects due to pharmacological interactions between 
herbal medicinal products and conventional therapies 
(Brazier et al., 2003). These are often underestimated for 
two main reasons: consumers generally consider herbal 
medicinal products “safe” because of their natural origin, 
and as self-care products they are often taken without 
consulting a physician (Rietjens et al., 2008).
The efficacy of drug therapy depends on many factors 
related to a drug’s pharmacokinetic and pharmacody-
namic properties, which can be modified by differences in 
genetic polymorphisms, age, gender, circadian rhythms, 
intestinal bacteria, pathophysiological conditions, 
pharmaceutical dosage form and xenobiotics (Terada & 
Inui, 2007; Franconi et al., 2007; Baraldo, 2008; Crozier 
et al., 2010; Colalto, 2010). One particular case is the 180
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co-administration of traditional drugs and herbal medici-
nal products (i.e. dietary supplements containing medici-
nal herbs or the herbal medicines traditionally used in 
phytotherapy for treating or preventing diseases), which 
may cause unexpected interactions (Izzo & Ernst, 2001).
Inhibition of CYPs, which are necessary for carcinogen 
activation, is a beneficial chemopreventive property of 
various flavonoids, but it may be a potential toxic property 
in flavonoid-drug interactions (Galati & O´Brien, 2004). 
Inhibition of CYP activities by flavonoids has been exten-
sively studied because of their potential use as agents 
blocking the initiation stage of carcinogenesis (Doostdar 
et al., 2000). Flavonoids can either inhibit or induce human 
CYPs depending upon their structure, concentration, or 
experimental conditions. Thus e.g. α-naphthoflavone is an 
inhibitor of human CYP1A1 and 1A2 (Tassaneeyakul et al., 
1993) but an inducer of CYP3A4 (Guengerich et al., 1994). 
The simultaneous administration of flavonoids and 
clinically used drugs may cause flavonoid-drug interac-
tions by modulating the pharmacokinetics of certain 
drugs, which results in an increase in their toxicity or 
a decline in their therapeutic effect, depending on the 
structure (Tang & Steams, 2001). Naringenin, a major 
flavanone present in grapefruit juice, exerts an inhibitory 
effect on intestinal CYP3A4 within 30 min and impairs 
the human metabolism of certain drugs such as those 
belonging to the class of calcium channel blockers (e.g., 
felodipine, nitrendipine, nisoldipine, verapamil) when 
co-administered with grapefruit juice (Fuhr, 1998). 
Indiscriminate use of herbal products can also alter the 
pharmacokinetics of certain drugs and result in increased 
drug toxicity. This issue is particularly important in assess-
ing the safety of concentrated flavonoid food supplements 
or herbal products particularly if their plasma concentra-
tions stay high after ingestion (Hodek et al., 2002; Galati & 
O´Brien, 2004). Inhibition of CYPs by flavonoids may also 
be a concern when non-therapeutic agents are consumed. 
By adding polar groups to these xenobiotics, CYPs play a 
role in enhancing their elimination. Although beneficial 
as a chemopreventive property, inhibition of CYPs by 
flavonoids may inhibit the metabolism and elimination of 
these nondrug compounds, increase their accumulation 
in vivo, and cause toxicity.
Phase II metabolism is generally regarded as a detoxi-
fication pathway and inhibition of these enzymes can lead 
to increased toxicity of a xenobiotic. Indeed, inhibition 
of glucuronosyltransferases (UGTs) by flavonoids, when 
taken concomitantly with a drug, can cause an overdose 
of the drug. Flavonoids have been shown to be substrates 
for UGTs and therefore, when taken in combination with 
certain drugs, they may inhibit their glucuronidation as a 
result of competitive inhibition (Galati & O´Brien, 2004). 
Natural substances benefi  cial for 
human health – future trends 
In general, the consumption of a diet low in fat and 
e nh an c e d  b y  frui ts  an d  v e g e ta b l e s ,  e s p e c i all y  ri c h  in  
phenolic compounds, may reduce risks of many civiliza-
tion diseases. Nowadays, informed patients increasingly 
demand substitution of prescription drugs by safer, often 
less expensive natural alternatives. Thus, the use of tra-
ditional medicines, mainly derived from plant sources, 
has become an attractive segment in the management of 
many lifestyle diseases.
Flavonoids may possess specific properties that can be 
beneficial for human health. However, as discussed, the 
experimental and in vitro data have produced conflicting 
results. The data from epidemiological studies regarding 
flavonoids in human health are far from convincing. This 
is especially disconcerting when specific flavonoids, such 
as genistein and quercetin are marketed as nutritional 
supplements, in which the concentrations in one dose 
could by far exceed the dose received from a daily veg-
etarian diet. The results of recent clinical studies should 
reinforce the need to proceed with caution in using flavo-
noid supplements. Whereas more studies at all levels are 
needed, to characterize both the potential health benefits 
of individual flavonoids and their potential harmful attri-
butes, it is very possible that the sum of the parts (e.g. total 
fruit and vegetable intake) is more important in providing 
a health benefit to humans than one plant constituent.
However, concerning the application of flavonoid-
based dietary supplements into common practice, the 
ongoing debate over possible adverse effects of certain 
n u tri e n ts  an d  d o sa g e  l ev e ls  is  o f  u tm o st  im po rtan c e .  
Nutritionists caution that large doses of virtually any 
vitamin or mineral may affect the body’s ability to absorb 
other nutrients and can be associated with some health 
risks. Thus toxicological aspects of unusually high doses 
for natural dietary supplements have to be assessed and 
the implication for public health considered. Future 
strategies looking into the synergistic effect of bioactive 
phytochemical components, specifically within the whole 
food matrix, fruits and/or vegetables including, would be 
desirable. In the meantime, incorporating 3–5 daily serv-
ings of either berry fruits or green leaf vegetables rich in 
flavonoids within the diet may be regarded as a proper 
choice for promoting health in the nowadays challenged 
organism.
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